The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Daklinza (daclatasvir)

When is Daklinza contraindicated?

The following chart provides information regarding potentially significant drug interactions with Daklinza (the table is not all-inclusive). Alteration in dose or regimen may be recommended based on drug interaction studies or predicted interactions. (For more information regarding the effect of co-administration of these medications with Daklinza and recommendations for alterations in dose or regimen please visit

Drug Class Specific Drugs Within Class Contraindicated with Daklinza
Strong CYP3A Inhibitors Atazanavir/ritonavir Clarithromycin Indinavir Itraconazole Ketoconazole Nefazodone Nelfinavir Posaconazole Saquinavir Telithromycin Voricanazole
Moderate CYP3A Inhibitors Atazanavir Ciprofloxacin Darunavir/ritonavir Diltiazem Erythromycin Fluconazole Fosamprenavir Verapamil
Moderate CYP3A Inducers Bosentan Dexamethasone Efavirenz Etravirine Modafinil Nafcillin Rifapentine
Anticoagulants Dabigatran Etexilate Mesylate
Cardiovascular Agents Amiodarone Digoxin
Lipid Lower Agents Atorvastatin Fluvastatin Pitavastatin Pravastatin Rosuvastatin Simvastatin

While the following drugs were evaluated in clinical trials, when used individually with Daklinza they had no clinically significant interactions:

  • cyclosporine
  • escitalopram
  • ethinyl estradiol/norgestimate
  • methadone
  • midazolam
  • tacrolimus
  • tenofovir

Last Updated: July 2015

FDA Approved Daklinza (Daclatasvir) for the Treatment of Patients with Chronic Hepatitis C Genotype 3., Bristol-Myers Squibb Company. Retrieved July 27, 2015.

Financial Help Info for Daklinza (daclatasvir) ., Bristol-Myers Squibb Company. Retrieved July 27, 2015.

Highlights of Prescribing Information - DAKLINZA., Bristol-Myers Squibb Company. Retrieved July 27, 2015.

Patient Support Connect., Bristol-Myers Squibb Company. Retrieved July 27, 2015.